IRIS
MELE, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 583
NA - Nord America 397
EU - Europa 216
SA - Sud America 186
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 2
Totale 1.422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 358
SG - Singapore 210
BR - Brasile 144
VN - Vietnam 111
CN - Cina 108
IT - Italia 100
HK - Hong Kong 39
BD - Bangladesh 35
FR - Francia 24
DE - Germania 23
FI - Finlandia 16
AR - Argentina 14
EC - Ecuador 14
MX - Messico 14
KR - Corea 13
IN - India 12
IQ - Iraq 10
GB - Regno Unito 9
RU - Federazione Russa 9
AT - Austria 8
CA - Canada 8
PK - Pakistan 7
TR - Turchia 7
UA - Ucraina 7
ZA - Sudafrica 7
ID - Indonesia 5
VE - Venezuela 5
PL - Polonia 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
ES - Italia 3
MA - Marocco 3
MY - Malesia 3
AU - Australia 2
CL - Cile 2
CO - Colombia 2
CR - Costa Rica 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
JM - Giamaica 2
JP - Giappone 2
KE - Kenya 2
KG - Kirghizistan 2
NI - Nicaragua 2
NL - Olanda 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
TN - Tunisia 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
CH - Svizzera 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IE - Irlanda 1
IL - Israele 1
JO - Giordania 1
KN - Saint Kitts e Nevis 1
MD - Moldavia 1
NP - Nepal 1
PY - Paraguay 1
RO - Romania 1
SE - Svezia 1
SN - Senegal 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 1.407
Salva come PNG Salva come JPEG
Città #
Singapore 100
San Jose 49
Ashburn 42
Ho Chi Minh City 42
Florence 38
Hong Kong 37
Council Bluffs 36
Beijing 27
Boardman 27
Dallas 24
Hefei 23
Hanoi 21
Los Angeles 15
New York 15
Milan 13
Seoul 13
São Paulo 13
Santa Clara 12
Lauterbourg 11
Munich 10
Shanghai 9
Helsinki 8
Charlotte 7
Rio de Janeiro 7
Chicago 6
Guayaquil 6
Mexico City 6
Quito 6
Vienna 6
Da Nang 5
Haiphong 5
Lahore 5
Lappeenranta 5
Porto Alegre 5
Rome 5
Sesto Fiorentino 5
Washington 5
Aracaju 4
Baghdad 4
Buffalo 4
Curitiba 4
Naples 4
Noto 4
Orem 4
Tashkent 4
Atlanta 3
Bari 3
Biên Hòa 3
Campinas 3
Frankfurt am Main 3
Hillsboro 3
Johannesburg 3
Montreal 3
Paris 3
Phoenix 3
Raipur 3
Santo Domingo 3
Thái Nguyên 3
Turku 3
Warsaw 3
Addis Ababa 2
Belo Horizonte 2
Bishkek 2
Bologna 2
Brooklyn 2
Bắc Giang 2
Bắc Ninh 2
Carney 2
Caxias do Sul 2
Chennai 2
Denver 2
Enfield 2
Fortaleza 2
Hưng Yên 2
Iporá 2
Juiz de Fora 2
Kingston 2
Kyiv 2
Lamezia Terme 2
Londrina 2
Managua 2
Nairobi 2
New Delhi 2
Ninh Bình 2
Nuremberg 2
Puchong 2
Recife 2
Ribeirão Preto 2
Riyadh 2
San José 2
San Luis 2
Secaucus 2
Sharjah 2
Sydney 2
Tokyo 2
Turin 2
Vancouver 2
Vĩnh Tường 2
Airdrie 1
Alvorada 1
Totale 824
Salva come PNG Salva come JPEG
Nome #
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 142
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 132
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 126
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 124
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 115
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 114
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 110
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 109
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 92
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study 90
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 82
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients 79
REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA 71
Imaging in Plasma‐Cell Neoplasms: Italian Experts’ Recommendations 24
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone 12
Totale 1.422
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.499
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.499
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202311 0 0 0 0 0 0 7 0 0 0 4 0
2023/2024122 2 2 22 20 8 15 8 1 1 2 5 36
2024/2025283 2 18 5 10 16 16 10 22 39 36 34 75
2025/2026922 94 54 68 71 142 62 111 60 83 78 47 52
2026/202784 60 24 0 0 0 0 0 0 0 0 0 0
Totale 1.422